News|Articles|March 27, 2020

In the Lab eNewsletter

  • Pharmaceutical Technology's In the Lab eNewsletter-04-01-2020
  • Volume 15
  • Issue 4

Pall’s Nanosep Centrifugal Device Offers High Nucleic Acid Binding Capacity

The new NAB Nanosep device provides increased binding capacity.

Pall’s newly introduced nucleic acid binding (NAB) Nanosep centrifugal device provides increased binding capacity through an innovative dual-layer, silica-based quartz glass fiber membrane. It can be used for applications that require highly efficient nucleic acid isolation.

Researchers using this multipurpose NAB Nanosep device can purify plasmid DNA, genomic DNA, or total RNA from a variety of starting materials. The centrifugal device can recover from 10,000 to 50 base pairs, allowing users to analyze the widest range of nucleic acid fragments in a single spin device, Pall announced in a March 11, 2020 press release.

The device offers flexibility and rapid processing without sacrificing yield or quality of the nucleic acids. Its double-layer membrane can isolate nucleic acids with yields high enough to allow multiple downstream applications, which can save time and cost by eliminating the need to process additional samples. The device has ultrasonically welded seals to prevent bypass contamination or seal failure and fits standard centrifuge rotors that accept 1.5-mL tubes.

The NAB Nanosep device is ideal for applications in the following workflows:

  • Purified plasmid DNA: restriction digest, cloning, and Sanger sequencing

  • Purified genomic DNA: quantitative polymerase chain reaction and next-generation sequencing

  • Purified total RNA: Reverse transcription polymerase chain reaction and cDNA library construction

Source: Pall


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.